Viread recommended for hepatitis B patients in England
This article was originally published in Scrip
Executive Summary
The National Institute for health and Clinical Excellence has published binding guidance that recommends Gilead Sciences' Viread (tenofovir disoproxil fumarate) as a treatment option for hepatitis B patients in the national health service in England and Wales.